Citius Pharmaceuticals (CTXR) Q3 2024 Annual Earnings
CTXR·Reported January 3, 2025·Before market open
Citius Pharmaceuticals reported Q3 2024 revenue of $155.9K, missed analyst consensus of $7.1M by $6.9M. Diluted EPS came in at $-1.75, missed the $-0.04 consensus by $1.71.
Revenue
$155.9Kmissed by $6.9M
Consensus: $7.1MDiluted EPS
$-1.75missed by $1.71
Consensus: $-0.04
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Citius Pharmaceuticals's Q3 2024 earnings report.
Citius Pharmaceuticals (CTXR) reported Q3 2024 earnings on January 3, 2025 before market open.
Citius Pharmaceuticals reported revenue of $155.9K and diluted EPS of $-1.75 for Q3 2024.
Revenue missed the consensus estimate of $7.1M by $6.9M. EPS missed the consensus estimate of $-0.04 by $1.71.
You can read the 10-K periodic report (0001213900-24-113149) directly on SEC EDGAR. The filing index links above go to sec.gov.